SPP Documents issued to Shareholders
SPP Documents issued to Shareholders
Brisbane, June 27, 2017 AEST (ABN Newswire) - Oventus Medical Limited (ASX:OVN) (Oventus) announced a share purchase plan (SPP) to the market on 22 June 2017. The record date to be registered as a shareholder for participation in the SPP is Wednesday, 21 June 2017.

Oventus is now in the process of mailing the SPP documents to its shareholders and, as required by the ASX Listing Rules, is releasing these documents to the market.

The following documents are being mailed to shareholders:

(a) offer letter and investment overview, which includes details on the pricing, timetable, intended use of funds and key risks of an investment in Oventus;

(b) SPP terms; and

(c) an application form.

If you have any questions about the SPP, please contact the offer information line on 1300-552-270 (within Australia) or +61-3-9415-4000 (outside Australia) between 9:00 a.m. and 5:00 p.m. (Brisbane time), Monday to Friday.

To view copies of these documents, please visit:
http://abnnewswire.net/lnk/IF0LF653


About Oventus Medical Ltd

Oventus Medical Ltd (ASX:OVN) is a Brisbane based medical device company that is commercialising a unique treatment platform for the treatment of sleep apnoea and snoring. Unlike other oral appliances or CPAP interfaces, the Oventus devices have a unique and patented airway within the treatment platform that allows air to flow to the back of the mouth unobstructed while maintaining an oral seal and stable jaw position, bypassing multiple obstructions from the nose, soft palate and tongue, reducing airway collapsibility and managing mouth breathing while maintaining a stable airway. They are particularly designed for the many people that have nasal obstructions and consequently tend to mainly breathe through their mouth. While it may seem counterintuitive, this technology actually manages mouth breathing by converting it to device breathing and normalising ventilation. The O2Vent is designed to allow nasal breathing when the nose is unobstructed, but when obstruction is present, breathing is supplemented via the airways in the appliance.

      


Contact

Dr Mel Bridges
Chairman
M: +61-41-3051-600

Kyahn Williamson
WE Buchan
P: +61-3-8866-1214
E: kwilliamson@buchanwe.com.au



Related Companies

Oventus Medical Ltd

ABN Newswire This Page Viewed:  (Last 7 Days: 7) (Last 30 Days: 46) (Since Published: 2591) 
ANALYTICS: LOGIN HERE

Oventus Medical Ltd NEWS: RECENT VISITS (4140)